Abnormal cell cycle regulation in primary human uveal melanoma cultures

Journal of Cellular Biochemistry

Volumn 93, Issue 4, 2004, Pages 708-720

  Pardo, María ^a,b   Piñeiro, Antonio ^b   De La Fuente, María ^b   García, Angel ^a   Prabhakar, Sripadi ^a   Zitzmann, Nicole ^a   Dwek, Raymond A ^a   Sánchez Salorio, Manuel ^b   Domínguez, Fernando ^c   Capeans, Carmen ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Instituto Galego de Oftalmoloxia INGO   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cell cycle; Rb; Uveal melanoma

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN; CARRIER PROTEIN; CYCLIN DEPENDENT KINASE; CYCLINE; DNA BINDING PROTEIN;

ARTICLE; CELL CULTURE; CELL CYCLE REGULATION; HUMAN; MELANOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; UVEA MELANOMA; ADULT; AGED; ANIMAL; CELL CYCLE; CHOROID TUMOR; CYTOLOGY; MACACA; MELANOMA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARRIER PROTEINS; CELL CYCLE; CHOROID NEOPLASMS; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA-BINDING PROTEINS; HUMANS; MACACA MULATTA; MELANOCYTES; MELANOMA; MIDDLE AGED; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 21744445108     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20230     Document Type: Article

References (58)

1. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer G. 2000. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 21:1-9.
2. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM. 2002. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31:301-305.
3. Aubert C, Rouge F, Reillaudou M, Metge P. 1993. Establishment and characterization of human ocular melanoma cell lines. Int J Cancer 54:784-792.
4. Bales ES, Dietrich C, Bandyopadhyay D, Schwahn DJ, Xu W, Didenko V, Leiss P, Conrad N, Pereira-Smith O, Orengo I, Medrano EE. 1999. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 113:1039-1046.
5. Bernstein SL, Wong P. 1998. Regional expression of disease-related genes in human and monkey retina. Mol Vis 4:24.
6. Bito LZ. 2001. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: The proctor lecture. Invest Ophthalmol Vis Sci 42:1126-1133.
7. Brantley MA, Jr., Harbour JW. 2000a. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 157:1795-1801.
8. Brantley MA, Jr., Harbour JW. 2000b. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 60:4320-4323.
9. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M. 2003. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17:1295-1297.
10. Burnier MN, Jr., McLean IW, Gamel JW. 1991. Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase. Cancer 68:809-814.
11. Capeans C, Piñeiro A, Domínguez F, Loidi L, Buceta M, Carneiro C, García-Caballero T, Sánchez-Salorio M. 1998. A c-myc antisense oligonuclotide inhibits human retinal pigment epithelial cell proliferation. Exp Eye Res 66:581-589.
12. Char DH, Huhta K, Waldman F. 1989. DNA cell cycle studies in uveal melanoma. Am J Ophthalmol 107:65-72.
13. Chen J, Wu X, Lin J, Levine AJ. 1996a. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452.
14. Chen CF, Chen Y, Dai K, Chen PL, Riley DJ, Lee WH. 1996b. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol Cell Biol 16: 4691-4699.
15. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO, Kim H. 2003. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63:2188-2193.
16. Cordon-Cardo C, Sheinfeld J, Dalbagni G. 1997. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 13:319-327.
17. Coupland SE, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N, Stein H. 1998. Expression pattern of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 82:961-970.
18. Diebold Y, Blanco G, Saornil MA, Fernández N, Lázaro MC. 1997. Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived). Curr Eye Res 16:487-495.
19. Dintilhac A, Bernues J. 2002. HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem 277:7021-7028.
20. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. 1988. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32:239-251.
21. Errico ME, Staibano S, Tranfa F, Bonavolonta G, Lo Muzio L, Somma P, Lucariello A, Mansueto G, D'Aponte A, Ferrara G, De Rosa G. 2003. Expression of cyclin-D1 in uveal malignant melanoma. Anticancer Res 23:2701-2706.
22. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
23. García A, Prabhakar S, Brock CJ, Pearce AC, Dwek RA, Watson SP, Hebestreit HF, Zitzmann N. 2004. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 4:656-668.
24. Goodall T, Buffey JA, Rennie IG, Benson M, Parsons MA, Faulkner MK, MacNeil S. 1994. Effect of melanocyte stimulating hormone on human cultured choroidal melanocytes, uveal melanoma cells, and retinal epithelial cells. Invest Ophthalmol Vis Sci 35:826-837.
25. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. 1986. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123:195-203.
26. Gronborg M, Kristiansen TZ, Stensballe A, Andersen JS, Ohara O, Mann M, Jensen ON, Pandey A. 2002. A mass spectrometry-based proteomic approach for identification of serine/theronine-phosphorylated proteins by enrichment with phospho-specific antibodies: Identification of a novel protein, Frigg, as a protein kinase A substrate. Mol Cell Proteomics 1:517-527.
27. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. 1988. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357.
28. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98:859-869.
29. Hassner A, Birnbaum D, Loew LM. 1984. Charge-shift probes of membrane potential synthesis. J Org Chem 49: 2546-2551.
30. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
31. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr., Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
32. Jemal A, Thomas A, Murray T, Thun M. 2002. Cancer statistics, 2002. CA Cancer J Clin 52:23-47.
33. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331-342.
34. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
35. Lai H, Ma F, Lai S. 2003. Identification of the novel role of pRB in eye cancer. J Cell Biochem 88:121-127.
36. Loercher AE, Harbour JW. 2003. Molecular genetics of uveal melanoma. Curr Eye Res 27:69-74.
37. Mancini MA, Shan B, Nickerson JA, Penman S, Lee WH. 1994. The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci USA 91:418-422.
38. Missotten GS, Journee-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ. 2003. Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci 44:3059-3065.
39. Morris EJ, Dyson NJ. 2001. Retinoblastoma protein partners. Adv Cancer Res 82:1-54.
40. Motokura T, Arnold A. 1993. Cyclin D and oncogenesis. Curr Opin Genet Dev 3:5-10.
41. Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F, Darbon JM. 1998. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci 39:876-884.
42. Mouriaux F, Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. 2000. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Invest Ophthalmol Vis Sci 41:2837-2843.
43. Mundle SD, Saberwal G. 2003. Evolving intricacies and implications of E2F1 regulation. FASEB J 17:569-574.
44. Nevins JR. 2001. The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
45. Nihei T, Takahashi S, Sagae S, Sato N, Kikuchi K. 1993. Protein interaction of retinoblastoma gene product pRb110 with M(r) 73,000 heat shock cognate protein. Cancer Res 53:1702-1705.
46. Ozaki T, Saijo M, Murakami K, Enomoto H, Taya Y, Sakiyama S. 1994. Complex formation between lamin A and the retinoblastoma gene product: Identification of the domain on lamin A required for its interaction. Oncogene 9:2649-2653.
47. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW. 1995. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55:2713-2718.
48. Rondinelli RH, Epner DE, Tricoli JV. 1997. Increased glyceraldehyde-3- phosphate dehydrogenase gene expression in late pathological stage human prostate cancer. Prostate Cancer Prostatic Dis 1:66-72.
49. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
50. Shevchenko A, Jensen ON, Podtelejnikov AV, Sagliocco F, Wilm M, Vorm O, Mortensen P, Shevchenko A, Boucherie H, Mann M. 1996. Linking genome and proteome by mass spectrometry: Large-scale identification of yeast proteins from two dimensional gels. Proc Natl Acad Sci USA 93: 14440-14445.
51. Singh AD, Topham A. 2003. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 110:962-965.
52. Svensson S, Nilsson K, Ringberg A, Landberg G. 2003. Invade or proliferate? Two contrasting events in malignant behaviour governed by p16 (INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 63:1737-1742.
53. Sánchez-Beato M, Camacho FI, Martínez-Montero JC, Saez AI, Villuendas R, Sánchez-Verde L, García JF, Piris MA. 1999. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94:765-772.
54. Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S, Nakachi K, Sueoka E. 2003. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRPN B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 40:45-53.
55. Wilson RP. 2000. The yearbook of ophthalmology. St. Louis: Mosby-Year Book.
56. Woitach JT, Zhang M, Niu CH, Thorgeirsson SS. 1998. A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. Nat Genet 19: 371-374.
57. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
58. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. 2003. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 3:617-633.